Current HIV Research - Volume 23, Issue 3, 2025
Volume 23, Issue 3, 2025
-
-
Navigating the COVID-19 Treatment Landscape: Efficacy and Side-Effects of Current Therapies against SARS-CoV-2
More LessCoronavirus Disease 2019 (COVID-19), caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China. Designated as an epidemic by the World Health Organization (WHO) on January 30, 2020, the virus quickly escalated to a global emergency, officially declared a pandemic in March 2020. With over 6 million recorded deaths and more than 200 identified symptoms in diverse individuals, the impact of COVID-19 is substantial. COVID-19 poses a greater risk to individuals with advanced HIV, while those with well-managed HIV are not at increased risk. Although COVID-19 vaccines are generally effective for people with HIV, some may experience reduced vaccine effectiveness and breakthrough infections due to suboptimal immune responses. Long COVID, affecting at least 65 million individuals, adds a layer of complexity. The virus's rapid mutation has led to diverse symptomatology, prompting adjustments in treatment guidelines. This review comprehensively examines repurposed antiviral drug candidates against COVID-19, explores immune responses across different age groups, delves into the mechanisms of COVID-19 vaccines, and discusses potential immunosuppressants. Additionally, the focus extends to Intravenous Immunoglobulin (IVIG), steroids, and anti-cytokine therapy as promising avenues to address cytokine release syndrome (CRS), a critical condition in COVID-19 patients.
-
-
-
Compromised Glycolysis in Memory CD4+ T Cells Derived from HIV-infected Immunological Non-responders to Highly Active Antiretroviral Therapy
More LessIntroduction/Objective“Immunological non-responders” (INRs) are individuals living with HIV who are undergoing Highly Active Antiretroviral Therapy (HAART) but fail to restore their CD4+ T-cells count despite effective viral control. The incomplete immune restoration in INRs is often associated with the low-productive proliferation of memory CD4+ T lymphocytes. The ability of CD4+ T cells to divide is critically dependent on the glycolytic pathway, which supplies the necessary energy and building blocks for cell division. We hypothesize that impaired glycolytic activity in the memory CD4+ T cells of INRs contributes to their ineffective proliferation, ultimately limiting immune restoration.
MethodsThis study involved two groups of HIV-infected HAART-treated subjects: INR and Immunological Responders (IR). A third group consisted of healthy controls, comprising uninfected volunteers. To identify the metabolic factors contributing to immunological non-response to therapy, glucose uptake, and lactate production were measured in the memory CD4+ T cells from all three groups.
ResultsINR had the highest activation level in memory CD4+ T cells and the greatest glucose uptake. However, both groups of HIV-infected patients had significantly reduced lactate production compared to the healthy donors. Short-term phytohemagglutinin stimulation provoked an increase in lactate production in memory CD4+ T lymphocytes. Nevertheless, we found significantly reduced lactate production levels in activated memory CD4+ Т cells of INR an IR.
ConclusionIn INRs, there is a discrepancy between the highly activated phenotype of memory CD4+ T lymphocytes and their glycolytic activity. This reduced glycolysis may explain the low-productive proliferation of memory CD4+ T lymphocytes in INRs.
-
-
-
Healthcare Providers' Perspectives on Same-Day Antiretroviral Initiation in Ethiopian Healthcare Facilities
More LessAuthors: Kidanu Hurisa Chachu and Kefiloe Adolphina MaboeBackgroundThe concept of same-day antiretroviral therapy (ART) initiation entails initiating HIV treatment promptly upon diagnosis, ideally during the initial clinic visit or even on the same day as diagnosis. This study explores the factors leading to patient loss to follow-up after same-day ART initiation and the benefits and challenges associated with this approach.
MethodsA qualitative research design was employed to investigate healthcare providers’ perspectives regarding same-day ART initiation and its contribution to patient loss to follow-up following same-day ART initiation, benefits, and challenges. It is a qualitative study conducted in the form of in-depth cell phone interviews with physicians and nurses who are providing ART services within healthcare facilities in Ethiopia. Data collection was conducted from April 30, 2021, to March 22, 2022.
ResultsThe findings revealed that same-day ART initiation offers both advantages and drawbacks. Findings show benefits such as shifts in perceptions and attitudes towards HIV, reduced transmission rates, enhanced service utilization, and viral suppression. However, disadvantages included its inappropriateness for critically ill patients’ refusal to accept results and suboptimal adherence, leading to increased risk of patient loss to follow-up.
ConclusionSame-day ART initiation presents a dual nature, offering immediate benefits in HIV management and transmission reduction, yet facing challenges regarding suitability for critically ill patients and adherence issues. The authors recommend addressing factors such as patient education, stigma reduction, and tailored interventions, which are crucial in optimizing the effectiveness of this approach and minimizing patient loss to follow-up.
-
-
-
Immunoinformatics Analysis of Potent Therapeutic Formulations for the Development of HIV-1 Nefmut-Carrying Engineered Exosomes
More LessAuthors: Parisa Moradi Pordanjani, Azam Bolhassani, Fatemeh Heidarnejad and Elnaz AgiBackgroundThe concept of designer exosomes involves developing engineered exosomes to overcome the limitations of natural exosomes in targeted drug delivery and vaccine development.
MethodsIn this study, the multiepitope constructs were designed based on immunogenic regions of mutant Nef protein of Human Immunodeficiency Virus-1 (HIV-1 Nefmut) that were prone to high Post-Translational Modifications (PTMs), such as palmitoylation and myristoylation. These constructs with high scores in PTMs were selected for interactions with molecules involved in exosome biogenesis, anchoring of a protein in membranes, and enzymes involved in PTMs (e.g., the mutant enzyme ZDHHC21 p.T209S). Moreover, the selected multiepitope construct with the highest PTM score and stable linkage with these molecules was fused to the first exon of the HIV-1 Tat protein as an antigen candidate, and to GFP as a tracking tool for evaluating their effects on the PTM scores and affinity binding with various molecules.
ResultsOur data demonstrated that the multiepitope construct No.13 had better scores for incorporation into exosomes compared to the whole sequences of Nefmut and wild-type Nef protein (Nefwt). Furthermore, the linkage of Tat protein to construct No. 13 did not hinder its loading in exosomes compared to GFP, suggesting the use of this construct in vaccine development.
ConclusionThe multiepitope construct No.13 harboring potent Nefmut epitopes can be applied for linkage with other viral antigens, enhancing their delivery into exosomes for therapeutic applications.
-
-
-
Access to Language Interpretation Services at Health Care Facilities Providing Care to Adults Diagnosed with HIV in the United States, 2019
More LessAuthors: Mabel Padilla, Linda Beer, Ruth E. Luna-Gierke, Tracy Tie, Jen-Feng Lu and John WeiserIntroductionPeople with limited English proficiency (LEP) experience barriers to healthcare access and optimal outcomes. Language interpretation services can facilitate clear communication-which is key to effective HIV care and treatment.
MethodsWe analyzed weighted data from the 2019 cycle of the Medical Monitoring Project (MMP), a cross-sectional, complex sample survey of U.S. adults with diagnosed HIV, and data from the 2021 MMP Facility Survey, a survey of facilities providing care to 2019 MMP respondents. We estimated the percentage of people with HIV (PWH) with LEP who received care at facilities offering language interpretation services and facilities providing language interpretation services, overall and by selected characteristics.
ResultsOverall, 89.9% of PWH with LEP received care at a facility with language interpretation services, and 83.6% of facilities provided language interpretation services. PWH with LEP who were unemployed were less likely than those who were employed to receive care at a facility with language interpretation services. Facilities that were Federally Qualified Health Centers, were not private practices, received Ryan White HIV/AIDS Program funding, and accepted public health care coverage were more likely to provide language interpretation services than facilities without these characteristics.
DiscussionMost PWH with LEP obtained HIV care at health care facilities providing language interpretation services, a positive finding as language is a common barrier to accessing care for people with LEP. Most facilities also provided language interpretation services, an important step towards ensuring meaningful access for people with LEP, as required by law.
ConclusionOur findings demonstrate that most HIV care facilities are providing access to language services to PWH with LEP in the United States.
-
Volumes & issues
-
Volume 23 (2025)
-
Volume 22 (2024)
-
Volume 21 (2023)
-
Volume 20 (2022)
-
Volume 19 (2021)
-
Volume 18 (2020)
-
Volume 17 (2019)
-
Volume 16 (2018)
-
Volume 15 (2017)
-
Volume 14 (2016)
-
Volume 13 (2015)
-
Volume 12 (2014)
-
Volume 11 (2013)
-
Volume 10 (2012)
-
Volume 9 (2011)
-
Volume 8 (2010)
-
Volume 7 (2009)
-
Volume 6 (2008)
-
Volume 5 (2007)
-
Volume 4 (2006)
-
Volume 3 (2005)
-
Volume 2 (2004)
-
Volume 1 (2003)
Most Read This Month